Kazumoto T, Mitsuhashi N, Hayakawa K, Yonome I, Niibe H
Department of Radiology, Gunma University School of Medicine, Japan.
Ann Nucl Med. 1993 Feb;7(1):39-44. doi: 10.1007/BF03164790.
IMACIS-1 is a radiopharmaceutical containing a mixture of Iodine-131 labeled monoclonal antibodies to CEA and CA19-9. IMACIS-1 immunoscintigraphy was evaluated for tumor detection in 7 primary lung cancer and 2 metastatic lung cancer patients who received radiotherapy. No adverse side effects due to IMACIS-1 were observed in this study. Positive detection was achieved in 5 of 9 patients (55.6%). It was less, but nearly the same as the detection rate obtained with Gallium-67 citrate (67Ga-citrate) in these patients. There was no clear correlation between IMACIS-1 accumulation and the CEA or CA19-9 serum levels. The IMACIS-1 positive detection rate decreased in many of the irradiated lesions. We considered that the decreased number of tumor cells and changes in blood perfusion are some of the factors controlling accumulation in tumors.
IMACIS-1是一种放射性药物，含有碘-131标记的针对癌胚抗原（CEA）和糖类抗原19-9（CA19-9）的单克隆抗体混合物。对7例原发性肺癌和2例接受放疗的转移性肺癌患者进行了IMACIS-1免疫闪烁显像以检测肿瘤。本研究中未观察到因IMACIS-1引起的不良副作用。9例患者中有5例（55.6%）检测呈阳性。该比例较低，但与这些患者使用枸橼酸镓（67Ga-枸橼酸盐）获得的检测率相近。IMACIS-1的聚集与CEA或CA19-9血清水平之间无明显相关性。许多受照射病灶的IMACIS-1阳性检测率下降。我们认为肿瘤细胞数量减少和血流灌注变化是控制肿瘤内聚集的一些因素。
